Ms. Marci Lieberman is currently a Lead Clinical Research Coordinator II (CRC II) for one of the largest Clinical Research Organizations (CRO) in the world. Ms. Lieberman has performed more than 3,000 hours of clinical research fieldwork, throughout which she has been Lead CRC on over 9 rare disease and standard clinical trials including Chronic Lyme Disease, Hereditary Angioedema, Immune Thrombocytopenia Purpura, and Chronic Migraine with Aura, as well as some of the most cutting-edge Vaccine clinical trials including mRNA-1010 Seasonal Influenza, mRNA-Covid SARS-CoV-2. Ms. Lieberman has demonstrated teamwork and cohesiveness in working with many clinical trial sponsors including Amgen, AstraZeneca, Abbvie, Moderna and Pfizer, to name a few, as well as with her colleagues and upper management. Ms. Lieberman is preparing for a certification as a Certified Senior Clinical Research Coordinator II (CCRC II) in October 2024, as well as having received a “Bachelor of Science in Clinical Research Award” from Clinical Research Fastrack on October 16th, 2021, for having completed 80 hours of clinical research training that prepared her to assist in the facilitation of clinical research trials and serves as proof of competence in research.
Ms. Lieberman’s journey in clinical research began in 2017 after she returned to America from a 3-month trip to Bad Aibling Germany, where she was cured from her Chronic Lyme Disease; diagnosed in summer of 2016. At the time, she was considered an entrepreneur, but her treatment at Klinik St. Georg ultimately led to her selling her largest business in 2019 and returning to school for a Master of Science in Psychology, emphasis in Forensic Psychology at Grand Canyon University; graduating class of 2022. Ms. Lieberman developed a form of empathy not understood by most: a warrior and survivor of an “invisible condition.” Thus, this experience would inevitably lead to much knowledge of Immunology and the desire to help those with these conditions. Since, she has performed as a Lead CRC IIMore...